Hui-Ting Peng

Timosaponin AⅢ and Gefitinib Synergistically Inhibit NSCLC by Targeting RAGE/AKT/NF-κB/VEGF Pathway.

INTRODUCTION EGFR tyrosine kinase inhibitors (EGFR-TKIs) are the standard therapy for EGFR-mutated advanced Non-Small Cell Lung Cancer (NSCLC). Gefitinib (GEF), as a first-generation EGFR-TKI, has made significant progress in the treatment of advanced lung cancer. However, acquired resistance leading to treatment failu...